Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23641829 | 0.85 | MMP2 (0.61) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL1041526 | 0.84 | MMP2 (0.60) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL6013478 | 0.84 | MMP2 (0.60) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL24346075 | 0.84 | MMP2 (0.60) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL9853256 | 0.84 | MMP2 (0.60) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL6013477 | 0.84 | MMP2 (0.60) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL21010316 | 0.83 | SLC15A1 (0.64) | MMP2ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL9556981 | 0.83 | MMP2 (0.58) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL2310428 | 0.82 | CYP3A4 (0.67) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL2310422 | 0.82 | CYP3A4 (0.67) | MMP2ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579325-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| EP-1294699-B1 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORP (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921547-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518999-B2 | Modulators of TNF-αsignaling | GENZYME CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | GENZYME | 2006-08-03 | — | — | US | disclosed |
| US-7034031-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-6969728-B2 | Antiinflammatory agents | GENZYME CORPORATION (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | MMP2 305/4885ALPI 2202/4885PKM 3964/4885 |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | TNF, TNFRSF1A, CD40 | MMP2 134/4885ALPI 748/4885PKM 2052/4885 |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | MMP2 1294/4885ALPI 3258/4885PKM 3039/4885 |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | TNF, TNFRSF1A, TNFRSF9 | MMP2 1294/4885ALPI 3258/4885PKM 3039/4885 |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | MMP2 1294/4885ALPI 3258/4885PKM 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.